Improving Lives Through Nuclear Medicine™

About

Company Overview

Jubilant Radiopharma is a global leader in the development, manufacturing, and commercialization of radiopharmaceuticals used for the diagnosis and treatment of disease. We serve our customers – and through them patients – with high-quality and reliable products and services.

We are passionately dedicated to advancing quality, sustainability, and supporting the entire nuclear medicine community.

Quality

The essence of Jubilant Radiopharma is a commitment to provide nuclear medicine professionals the highest quality radiopharmaceuticals so as to give the highest quality care to their patients.

Our manufacturing facilities are cGMP compliant and ISO 13485 certified.

We are committed to:

  • Excellence in every aspect of its business in order to provide high-quality and safe radiopharmaceutical products
  • Achieving an effective Quality Management System that is compliant with customer standards and regulatory requirements
  • Continuous improvement through advanced technology and innovation

Sustainability

For more than 60 years, Jubilant Radiopharma has been exclusively focused on supplying radiopharmaceutical products to nuclear medicine practitioners. We understand the importance of a consistent and reliable supply of high-quality radiopharmaceuticals to ensure uninterrupted patient care.

Value

Jubilant Radiopharma supports healthcare professionals to help them realize the greatest value from the nuclear medicine procedures they perform; delivering high-quality care, reducing costs, and improving the patient experience. This requires providing exceptional service, as well as investing in the development of radiopharmaceuticals and technologies to advance the growth and expansion of nuclear medicine.

We continuously strive to showcase the value of nuclear medicine by funding physician initiated research and pharmacoeconomic studies that highlight the benefits of nuclear medicine to both physicians and patients.

Studies include:

  • Studies looking at the impact of V/Q Scan and CTPA Procedures on Healthcare Resource Use and Cost1
  • A 10-year retrospective study showing that younger women are more likely to receive CTPA than V/Q2
  • Thyroid Cancer Center Research funding

References:

1. Casciano, J, et al, Impact of Ventilation Perfusion Scan and Computed Tomography Pulmonary Angiogram Procedures on Healthcare Resource Use and Cost [abstract16-009], Amer College of Rad, 2016

2. Casciano, J, et al, Insurance claims linked medical records review in ~80,000 patients focused on V/Q and CTPA imaging in PE shows that younger women are more likely to receive CTPA: A 10 year retrospective analysis of hospital administrative data, J Nucl Med, May 1, 2016 vol. 57 no. 2,1655

Jubilant Pharma

Jubilant Radiopharma is a subsidiary of Jubilant Pharma.

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organise our phrama business into three segments. Firstly, ‘Specialty Pharmaceuticals’ comprising Radiopharmaceuticals (including Radiopharmacies) and Allergy Therapy Products. Secondly, our ‘CDMO’ segment, comprising Parenteral Contract Manufacturing and Active Pharmaceutical Ingredients. Finally, the ‘Generics’ segment is for our Finished Dosage Formulations business.

We supply our products and services to customers in over 85 countries. We have four manufacturing facilities in North America and two in India, coupled with research and development centers in North America and India. Additionally, we have a distribution network of more than 50 radiopharmacies in the United States.

To find out more about Jubilant Pharma, please click here.

Jubilant Life Sciences

Jubilant Life Sciences Limited is the parent company of Jubilant Pharma. It’s an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Jubilant Life Sciences has a team of around 8,000 multicultural people across the globe and is committed to delivering value to its customers in over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies worldwide.

To find out more about Jubilant Life Sciences, please click here.

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.